Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_2
2
18%
Ph phase_1
8
73%

Phase Distribution

8

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(3)
Other(1)

Detailed Status

Completed7
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
70.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (72.7%)
Phase 22 (18.2%)
Phase 31 (9.1%)

Trials by Status

completed764%
terminated327%
unknown19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

NCT03165955
terminatedphase_1

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

NCT03892018
completedphase_2

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

NCT03544567
terminatedphase_1

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03588039
completedphase_3

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

NCT02594371
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03165955Phase 1

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Completed
NCT03892018Phase 1

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
NCT03544567Phase 2

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Completed
NCT03588039Phase 1

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Terminated
NCT02594371Phase 3

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Completed
NCT04168957Phase 1

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Terminated
NCT02970539Phase 1

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Unknown
NCT02730481Phase 1

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Completed
NCT04993040Phase 1

A PK Study of Oraxol in Breast Cancer Patients

Completed
NCT04180384Phase 2

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Completed
NCT01967043Phase 1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11